ESUN

Enhanced Scope and New Publication Schedule

By Bruce Shriver, PhD
Editor-in-Chief, ESUN

ESUN's Scope: Starting with this issue, ESUN will have an enhanced scope. In addition to our feature articles focusing on evidence-based topics on any aspect of sarcoma, we are now also soliciting shorter format pieces, entitled "Opinions and Hypotheses," that are intended as contributions to public debate relevant to any aspect of sarcoma. These articles should typically be between 800 and 1500 words. They need not be exhaustively referenced, and they should present substantive, novel and/or provocative ideas of interest to the sarcoma community. Areas of interest range from the genetic determinants of personalized medicine to the public implications of rare and orphan diseases. We will publish correspondence regarding all articles, reserving the right of authors to respond to comment.

ESUN's Publication Schedule: For many years ESUN was published bimonthly on the 15th of month beginning with February. As of this issue, we will continue to publish ESUN bimonthly, but on the 1st of January, March, May, July, September and November. Our peer-review process typically takes 2-3 months. The publishing schedule for the next six issues is:

ESUN's Readership: Our readership consists of physicians, nurses, patients, caregivers and survivors. ESUN’s contents are accessed over 30,000 times each month, giving wide visibility to the published articles. A number of ESUN articles have been translated by sarcoma physicians and researchers and appear in Chinese, French, German, Italian, Japanese, Polish, Portuguese and Spanish to benefit the sarcoma Communities within the respective countries.

Contact: Please write to Bruce if you are interested in: (a) submitting an article or an Opinions and Hypotheses piece to ESUN for consideration; (ii) reviewing articles; or (iii) translating articles. Please let me know what topics you are interested in and I will be happy to send you the Guidelines for Authors and the Guidelines for Reviewers. If you are interested in translating articles, please specify the language(s).